{"componentLayouts":{"ComponentLayout-1":{"columnRange":{"length":8,"start":0},"contentInset":{"bottom":false,"left":true,"right":true,"top":false},"identifier":"ComponentLayout-1","ignoreDocumentMargin":"both","margin":{"bottom":"25.0pt","top":"0.0pt"}},"ComponentLayout-10":{"columnRange":{"length":7,"start":0},"identifier":"ComponentLayout-10","margin":{"bottom":"20.0pt","top":"0.0pt"}},"ComponentLayout-12":{"columnRange":{"length":8,"start":0},"identifier":"ComponentLayout-12","ignoreDocumentMargin":"both","margin":{"bottom":"0.0pt","top":"14.0pt"}},"ComponentLayout-2":{"columnRange":{"length":8,"start":0},"identifier":"ComponentLayout-2","ignoreDocumentMargin":"none","margin":{"bottom":"15.0pt","top":"28.0pt"}},"ComponentLayout-3":{"columnRange":{"length":8,"start":0},"identifier":"ComponentLayout-3","ignoreDocumentMargin":"none","margin":{"bottom":"28.0pt","top":"20.0pt"}},"ComponentLayout-4":{"columnRange":{"length":8,"start":0},"identifier":"ComponentLayout-4","margin":{"bottom":"24.0pt","top":"0.0pt"}},"_defaultComponentLayout":{"columnRange":{"length":8,"start":0},"identifier":"_defaultComponentLayout"},"blockquote-body":{"columnRange":{"length":6,"start":1},"contentInset":{"bottom":true,"left":true,"right":true,"top":true},"identifier":"blockquote-body","margin":{"bottom":"0.0pt","top":"0.0pt"}},"blockquote-container":{"columnRange":{"length":7,"start":0},"contentInset":{"bottom":true,"left":true,"right":true,"top":true},"identifier":"blockquote-container","margin":{"bottom":"28.0pt","top":"0.0pt"}},"bottom-banner-body":{"columnRange":{"length":8,"start":0},"identifier":"bottom-banner-body","margin":{"bottom":"30.0pt","top":"0.0pt"},"minimumHeight":"38.0pt"},"bottom-banner-head":{"columnRange":{"length":8,"start":0},"identifier":"bottom-banner-head","ignoreDocumentMargin":"none","margin":{"bottom":"13.0pt","top":"16.0pt"}},"default-author":{"columnRange":{"length":7,"start":0},"identifier":"default-author","margin":{"bottom":"24.0pt","top":"8.0pt"}},"default-body":{"columnRange":{"length":7,"start":0},"identifier":"default-body","margin":{"bottom":"24.0pt","top":"0.0pt"}},"default-caption":{"columnRange":{"length":8,"start":0},"identifier":"default-caption","margin":{"bottom":"0.0pt","top":"2.0pt"}},"default-gallery":{"columnRange":{"length":8,"start":0},"identifier":"default-gallery","margin":{"bottom":"10.0pt","top":"0.0pt"}},"default-section":{"columnRange":{"length":8,"start":0},"identifier":"default-section","ignoreDocumentMargin":"both"},"default-title":{"columnRange":{"length":8,"start":0},"identifier":"default-title","margin":{"bottom":"0.0pt","top":"10.0pt"}},"fullbleed-image":{"columnRange":{"length":8,"start":0},"identifier":"fullbleed-image","ignoreDocumentMargin":"both","margin":{"bottom":"10.0pt","top":"2.0pt"}},"heading1":{"columnRange":{"length":7,"start":0},"identifier":"heading1","ignoreDocumentMargin":"none","margin":{"bottom":"15.0pt","top":"0.0pt"}},"heading3":{"columnRange":{"length":8,"start":0},"identifier":"hea ding3","ignoreDocumentMargin":"none","margin":{"bottom":"15.0pt","top":"0.0pt"}},"heading4":{"columnRange":{"length":7,"start":0},"identifier":"heading4","ignoreDocumentMargin":"none","margin":{"bottom":"15.0pt","top":"10.0pt"}},"image-container":{"columnRange":{"length":8,"start":0},"identifier":"image-container","ignoreDocumentMargin":"both","margin":{"bottom":"28.0pt","top":"0.0pt"}},"inset":{"columnRange":{"length":7,"start":0},"identifier":"inset"},"kicker":{"columnRange":{"length":8,"start":0},"identifier":"kicker","margin":{"bottom":"0.0pt","top":"8.0pt"}},"related-coverage-heading":{"columnRange":{"length":7,"start":0},"identifier":"related-coverage-heading","margin":{"bottom":"16.0pt","top":"0.0pt"}},"related-link":{"columnRange":{"length":6,"start":0},"identifier":"related-link","margin":{"bottom":"20.0pt","top":"0.0pt"}},"small-caption":{"columnRange":{"length":7,"start":0},"identifier":"small-caption","margin":{"bottom":"2.0pt","top":"2.0pt"}},"small-image":{"columnRange":{"length":7,"start":0},"identifier":"small-image","margin":{"bottom":"10.0pt","top":"0.0pt"}},"video":{"columnRange":{"length":8,"start":0},"identifier":"video","ignoreDocumentMargin":"both","margin":{"bottom":"0.0pt","top":"0.0pt"}}},"componentStyles":{"_anf-cs-1":{"backgroundColor":"#F7F7F7","identifier":"_anf-cs-1"},"_anf-cs-2":{"backgroundColor":"#3883e8","identifier":"_anf-cs-2"},"_anf-cs-3":{"fill":{"fillMode":"fit","horizontalAlignment":"center","imageIdentifier":"f589f0963b351d47bf2a6ea96a46d9d2","type":"image","verticalAlignment":"center"},"identifier":"_anf-cs-3"},"blockquote":{"border":{"left":{"color":"#E2E2E2","style":"solid","width":"1.0pt"}},"identifier":"blockquote"},"default-section":{"backgroundColor":"#FFFFFF","identifier":"default-section"}},"componentTextStyles":{"blockquote":{"fontName":"NYTImperial-Regular","fontSize":17,"identifier":"blockquote","lineHeight":22,"linkStyle":{"fontSize":17,"textColor":"#326891"},"textAlignment":"left","textColor":"#909090"},"bottom-banner-body":{"fontName":"NYTFranklin-Bold","fontSize":15,"identifier":"bottom-banner-body","lineHeight":45,"linkStyle":{"fontSize":15,"textColor":"#3583BC"},"textAlignment":"center","textColor":"#FFFFFF"},"bottom-banner-head":{"fontName":"NYTFranklin-Bold","fontSize":14,"identifier":"bottom-banner-head","lineHeight":21,"textAlignment":"center","textColor":"#111111"},"default":{"fontName":"NYTImperial-Regular","fontSize":17,"identifier":"default","lineHeight":24,"linkStyle":{"textColor":"#326891"},"textAlignment":"left","textColor":"#222222"},"default-author":{"fontName":"NYTCheltenhamSH-Bold","fontSize":12,"identifier":"default-author","lineHeight":16,"textAlignment":"left","textColor":"#222222"},"default-body":{"fontName":"NYTImperial-Regular","fontSize":17,"hyphenation":false,"identifier":"default-body","lineHeight":25,"textAlignment":"left","textColor":"#222222"},"default-caption":{"fontName":"NYTCheltenhamSH-Regular","fontSize":12,"identifier":"default-caption","lineHeight":15,"t extAlignment":"left","textColor":"#666666"},"default-heading1":{"fontName":"NYTCheltenham-Medium","fontSize":48,"identifier":"default-heading1","lineHeight":48},"default-heading2":{"fontName":"NYTCheltenham-Medium","fontSize":46,"identifier":"default-heading2","lineHeight":46},"default-heading3":{"fontName":"NYTCheltenham-Medium","fontSize":44,"identifier":"default-heading3","lineHeight":44},"default-heading4":{"fontName":"NYTCheltenham-Medium","fontSize":38,"identifier":"default-heading4","lineHeight":38},"default-heading5":{"fontName":"NYTCheltenham-Medium","fontSize":36,"identifier":"default-heading5","lineHeight":36},"default-heading6":{"fontName":"NYTCheltenham-Medium","fontSize":30,"identifier":"default-heading6","lineHeight":30},"default-title":{"fontName":"NYTCheltenham-BoldItalic","fontSize":44,"identifier":"default-title","lineHeight":46,"textAlignment":"left","textColor":"#222222"},"footer-text":{"fontName":"NYTFranklin-Medium","fontSize":14,"identifier":"footer-text","lineHeight":18,"textAlignment":"left","textColor":"#222222"},"kicker":{"fontName":"NYTFranklin-Medium","fontSize":13,"identifier":"kicker","lineHeight":14,"textTransform":"uppercase","tracking":0.02},"related-coverage":{"fontName":"NYTFranklin-Bold","fontSize":14,"identifier":"related-coverage","textTransform":"uppercase","tracking":0.02},"related-link":{"fontName":"NYTCheltenham-Medium","fontSize":21,"identifier":"related-link","linkStyle":{"textColor":"#326891"},"textColor":"#909090"},"top-newsletter-promo-text-style":{"fontName":"NYTFranklin-Medium","fontSize":21,"hyphenation":false,"identifier":"top-newsletter-promo-text-style","lineHeight":27,"linkStyle":{"fontName":"NYTFranklin-Medium","fontSize":21,"textColor":"#fff"},"textAlignment":"center","textColor":"#fff"}},"components":[{"components":[{"components":[{"identifier":"_anf-divider-1","layout":"ComponentLayout-2","role":"divider","stroke":{"color":"#ffffff30","width":"1.0pt"},"type":"line"},{"additions":[{"URL":"https://www.nytimes.com/newsletters/newyorktoday?partner=applenews&ad-keywords=APPLEMOBILE&region=header&asset_id=100000006090758","range":{"length":119,"start":0},"type":"link"}],"identifier":"_anf-body-1","inlineTextStyles":[{"range":{"length":42,"start":77},"textStyle":"_anf-ts-101"}],"layout":"_defaultComponentLayout","role":"body","text":"Get the latest on New York businesses, arts, sports, dining, style and more. Sign up for the New York Today newsletter.","textStyle":"top-newsletter-promo-text-style","type":"text"},{"identifier":"_anf-divider-2","layout":"ComponentLayout-3","role":"divider","stroke":{"color":"#ffffff30","width":"1.0pt"},"type":"line"}],"identifier":"top-newsletter-promo-banner","layout":"ComponentLayout-1","role":"container","style":"_anf-cs-2","type":"container"},{"identifier":"_anf-title-1","layout":"default-title","role":"title","text":"A G.O.P. Senate Candidate Highlights His Drug Industry Career. Should He?","type":"text"},{"identifier":"_anf-author-1","inlineTextStyles":[{"r ange":{"length":16,"start":35},"textStyle":"pub-dt"}],"layout":"default-author","role":"author","text":"By KATIE THOMAS and NICK CORASANITI SEPT. 24, 2018 ","type":"text"}],"identifier":"_anf-section-1","layout":"default-section","role":"section","type":"section"},{"components":[{"components":[{"caption":"Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Leonard Lance of New Jersey and former Gov. Chris Christie. Mel Evans/Associated Press","captionComponent":{"text":"Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Leonard Lance of New Jersey and former Gov. Chris Christie. Mel Evans/Associated Press"},"identifier":"100000006098011_5ba8b80411187","imageIdentifier":"e126e7bde26613f50f2609cb8776d827","layout":"fullbleed-image","role":"photo","type":"scalable_image"},{"identifier":"_anf-caption-1","inlineTextStyles":[{"range":{"length":27,"start":261},"textStyle":"photo-credit"}],"layout":"default-caption","role":"caption","text":"Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Leonard Lance of New Jersey and former Gov. Chris Christie. Mel Evans/Associated Press ","type":"text"}],"identifier":"_anf-container-5","layout":"image-container","role":"container","type":"container"}],"identifier":"_anf-section-2","layout":"default-section","role":"section","scene":{"fadeColor":"#FFFFFF","type":"fading_sticky_header"},"type":"section"},{"additions":[{"URL":"https://www.businesswire.com/news/home/20180129005762/en/Celgene-Announces-Retirement-Executive-Chairman-Bob-Hugin","range":{"length":34,"start":194},"type":"link"}],"identifier":"_anf-body-6","inlineTextStyles":[{"range":{"length":363,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":363,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"When Bob Hugin joined Celgene in 1999 as its chief financial officer, the company was a struggling biotech that sold just one product — a leprosy drug — and faced a shaky future. By the time he stepped down as executive chairman in February to run for United States Senate, Celgene had become a pharmaceutical powerhouse with a market value of nearly $80 billion.","type":"text"},{"additions":[{"URL":"https://ir.celgene.com/press-releases/press-release-details/2018/Celgene-Reports-Fourth-Quarter-and-Full-Year-2017-Operating-and-Financial-Results/default.aspx","range":{"length":17,"start":177},"type":"link"}],"identifier":"_anf-body-7","inlineTextStyles":[{"range":{"length":195,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":195,"start":0},"textStyle":"_anf-ts-1"}],"layout":"de fault-body","role":"body","text":"And that onetime leprosy drug? It had been transformed into Revlimid, a best-selling cancer drug that, with annual sales of $8.2 billion, made up nearly two-thirds of Celgene’s net sales in 2017.","type":"text"},{"additions":[{"URL":"https://youtu.be/K4AqlkLfs5w","range":{"length":34,"start":174},"type":"link"}],"identifier":"_anf-body-8","inlineTextStyles":[{"range":{"length":324,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":324,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Mr. Hugin, a Republican mounting a surprisingly strong challenge to Senator Robert Menendez in New Jersey, has made his career at Celgene a cornerstone of his campaign, with television advertisements boasting that he “chose a life of service” in the Marines and “leading a health care company that develops cancer medicine.”","type":"text"},{"identifier":"_anf-body-9","inlineTextStyles":[{"range":{"length":299,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":299,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"In deeply blue New Jersey, few expected a real contest for Mr. Menendez’s seat. Yet anger stemming from Mr. Menendez’s federal corruption trial last year — a trial that Mr. Hugin’s campaign reminds television viewers in New Jersey about on a regular basis — has dampened his popularity among voters.","type":"text"},{"bannerType":"any","identifier":"_anf-banner_advertisement-1","layout":"ComponentLayout-4","role":"banner_advertisement","type":"banner_advertisement"},{"additions":[{"URL":"https://twitter.com/realDonaldTrump/status/1016368503723577344","range":{"length":21,"start":213},"type":"link"},{"URL":"https://news.gallup.com/poll/12748/business-industry-sector-ratings.aspx","range":{"length":16,"start":238},"type":"link"}],"identifier":"_anf-body-10","inlineTextStyles":[{"range":{"length":413,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":413,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"But Mr. Hugin’s professional career could also prove to be a liability — he is the sole pharmaceutical executive running for statewide office in 2018. Anger over high drug prices has risen and President Trump has vilified the industry. A 2017 Gallup poll found that just 33 percent of the country had a favorable view of the drug industry, the second-lowest of any sector. (The lowest was the federal government.)","type":"text"},{"identifier":"_anf-body-11","inlineTextStyles":[{"range":{"length":394,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":394,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"An examination of Celgene’s aggressive promotion of Revlimid and its predecessor, Thalomid, while Mr. Hugin was a top executive at the company, including its chief executive for six years, reveals many of the controversial financial and legal tactics that have tarnished the industry’s reputat ion, from marketing drugs for unapproved uses to raising prices and fighting off generic competitors.","type":"text"},{"additions":[{"URL":"https://www.nytimes.com/2017/07/25/health/celgene-to-pay-280-million-to-settle-fraud-suit-over-cancer-drugs.html?partner=applenews&ad-keywords=APPLEMOBILE&region=written_through&asset_id=100000006090758","range":{"length":53,"start":19},"type":"link"}],"identifier":"_anf-body-12","inlineTextStyles":[{"range":{"length":362,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":362,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Last year, Celgene paid $280 million to settle a whistle-blower lawsuit claiming it had inappropriately promoted Revlimid and Thalomid to treat a range of cancers beyond what the Food and Drug Administration had approved. Several generic drug companies have sued the company claiming that Celgene denied them access to drug samples needed to make cheaper copies.","type":"text"},{"additions":[{"URL":"https://www.youtube.com/watch?v=RIfs6hthwGo","range":{"length":71,"start":138},"type":"link"}],"identifier":"_anf-body-13","inlineTextStyles":[{"range":{"length":334,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":334,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Mr. Hugin has also been targeted by a super PAC run by a cancer patient taking Revlimid that launched a $1.5 million advertising campaign criticizing steep price hikes of cancer drugs during Mr. Hugin’s tenure at Celgene. And the Menendez campaign has attacked him around drug prices, personal profits and the $280 million settlement.","type":"text"},{"bannerType":"any","identifier":"_anf-banner_advertisement-2","layout":"ComponentLayout-4","role":"banner_advertisement","type":"banner_advertisement"},{"identifier":"_anf-body-14","inlineTextStyles":[{"range":{"length":38,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":38,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Mr. Hugin has dismissed the criticism.","type":"text"},{"identifier":"_anf-body-15","inlineTextStyles":[{"range":{"length":317,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":317,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"“New Jersey voters are a lot smarter than my opponent gives them credit for,” Mr. Hugin said in a statement. “They understand that it costs billions of dollars in research and development, and years of hard work by hundreds of researchers and scientists, to develop medicines that successfully treat and cure cancer.”","type":"text"},{"identifier":"_anf-body-16","inlineTextStyles":[{"range":{"length":237,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":237,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Some experts are not so sure. Patrick Murray, director of the Monmouth University Poll, noted that despite the fact that many large drug companies are b ased in New Jersey, public opinion in the state likely mirrors the national attitude.","type":"text"},{"identifier":"_anf-body-17","inlineTextStyles":[{"range":{"length":228,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":228,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"“Concern about being able to afford health care is the top issue mentioned by voters in our polling for this year’s midterm, in large part because of rising drug costs,” Mr. Murray said. “This provides an opening for Menendez.’’","type":"text"},{"components":[{"caption":"Mr. Menendez has attacked Mr. Hugin’s record as a pharmaceutical executive, accusing him of profiting from major price increases for cancer drugs. Bryan Anselm for The New York Times","captionComponent":{"text":"Mr. Menendez has attacked Mr. Hugin’s record as a pharmaceutical executive, accusing him of profiting from major price increases for cancer drugs. Bryan Anselm for The New York Times"},"identifier":"100000006098032_5ba8b80411dfc","imageIdentifier":"5e5526aaedbd7af8c8bade0a70b11da0","layout":"fullbleed-image","role":"photo","type":"scalable_image"},{"identifier":"_anf-caption-2","inlineTextStyles":[{"range":{"length":36,"start":146},"textStyle":"photo-credit"}],"layout":"default-caption","role":"caption","text":"Mr. Menendez has attacked Mr. Hugin’s record as a pharmaceutical executive, accusing him of profiting from major price increases for cancer drugs. Bryan Anselm for The New York Times ","type":"text"}],"identifier":"_anf-container-1","layout":"image-container","role":"container","type":"container"},{"identifier":"_anf-body-18","inlineTextStyles":[{"range":{"length":277,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":277,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Any broad swing in voter opinion could prove difficult for Mr. Hugin to overcome. Even with Mr. Menendez’s vulnerabilities, New Jersey has nearly 900,000 more registered Democrats than Republicans, and a number of competitive House races that have attracted national attention.","type":"text"},{"bannerType":"any","identifier":"_anf-banner_advertisement-3","layout":"ComponentLayout-4","role":"banner_advertisement","type":"banner_advertisement"},{"identifier":"_anf-heading4-1","layout":"heading4","role":"heading4","text":"A once-notorious drug becomes a lucrative cancer weapon","type":"text"},{"identifier":"_anf-body-19","inlineTextStyles":[{"range":{"length":235,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":235,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"When Mr. Hugin arrived at Celgene in June 1999, the company was struggling to figure out how to turn a profit on its only marketed drug, Thalomid, which had been approved a year earlier to treat a rare skin condition caused by leprosy.","type":"text"},{"identifier":"_anf-body-20","inlineTextStyles":[{"range":{"length":158,"start":0},"textStyle":"_anf-ts-1"} ,{"range":{"length":158,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Thalomid was Celgene’s brand name for thalidomide, an old drug that became notorious in the 1960s after it was traced to thousands of birth defects worldwide.","type":"text"},{"additions":[{"URL":"https://www.nytimes.com/1997/11/28/us/thalidomide-once-banned-is-in-demand.html?partner=applenews&ad-keywords=APPLEMOBILE&region=written_through&asset_id=100000006090758","range":{"length":61,"start":55},"type":"link"},{"URL":"https://www.nytimes.com/1997/11/28/us/thalidomide-once-banned-is-in-demand.html?partner=applenews&ad-keywords=APPLEMOBILE&region=written_through&asset_id=100000006090758","range":{"length":11,"start":116},"type":"link"}],"identifier":"_anf-body-21","inlineTextStyles":[{"range":{"length":358,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":358,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Thalidomide had fallen into obscurity until the 1990s, when new research suggested it could be useful for a variety of diseases. AIDS activists were smuggling it into the country and selling it through black-market “buyers clubs” after research suggested the drug could be used for AIDS wasting syndrome and Kaposi sarcoma, two serious complications of AIDS.","type":"text"},{"identifier":"_anf-body-22","inlineTextStyles":[{"range":{"length":187,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":187,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"F.D.A. officials, alarmed that a notorious drug was being sold illicitly, took the unusual step of seeking out drug companies that might be willing to bring thalidomide to market legally.","type":"text"},{"bannerType":"any","identifier":"_anf-banner_advertisement-4","layout":"ComponentLayout-4","role":"banner_advertisement","type":"banner_advertisement"},{"identifier":"_anf-body-23","inlineTextStyles":[{"range":{"length":109,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":109,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"Celgene, then a little-known New Jersey company that had never sold a drug, ultimately took up the challenge.","type":"text"},{"additions":[{"URL":"https://www.hrsa.gov/hansens-disease/clinical-center.html","range":{"length":38,"start":113},"type":"link"}],"identifier":"_anf-body-24","inlineTextStyles":[{"range":{"length":251,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":251,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-body","role":"body","text":"In 1998, Celgene’s application was approved to treat erythema nodosum leprosum, a complication of leprosy, which is extremely rare in the United States. In 2007, Celgene said that just 100 prescriptions a year were written to treat the skin condition.","type":"text"},{"identifier":"_anf-body-25","inlineTextStyles":[{"range":{"length":256,"start":0},"textStyle":"_anf-ts-1"},{"range":{"length":256,"start